NCT04631744 - Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions

Prostate Cancer

Interventions

DRUG

Cabozantinib

Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily

Trial Locations (4)

RECRUITING

Columbia University Irving Medical Center, New York

RECRUITING

Weill Cornell Medicine, New York

RECRUITING

University of Pittsburgh Medical Center (UPMC), Pittsburgh

RECRUITING

Karmanos Cancer Institute, Detroit